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Summary
Insulin resistance is a primary defect in type 2 diabetes characterized by impaired peripheral glucose uptake and insufficient
suppression of hepatic glucose output. Insulin signaling inhibits liver glucose production by inducing nuclear exclusion of
the gluconeogenic transcription factor FOXO1 in an Akt-dependent manner. Through the concomitant application of ge-
nome-scale functional screening and quantitative image analysis, we have identified PTP-MEG2 as a modulator of insu-
lin-dependent FOXO1 subcellular localization. Ectopic expression of PTP-MEG2 in cells inhibited insulin-induced phosphor-
ylation of the insulin receptor, while RNAi-mediated reduction of PTP-MEG2 transcript levels enhanced insulin action.
Additionally, adenoviral-mediated depletion of PTP-MEG2 in livers of diabetic (db/db) mice resulted in insulin sensitization
and normalization of hyperglycemia. These data implicate PTP-MEG2 as a mediator of blood glucose homeostasis through
antagonism of insulin signaling, and suggest that modulation of PTP-MEG2 activity may be an effective strategy in the treat-
ment of type 2 diabetes.Introduction
In the fasted state, glucose is synthesized by the liver tomaintain
euglycemia (Barthel and Schmoll, 2003). When blood glucose
levels are elevated after nutrient ingestion, endogenous glucose
production is downregulated. This response is primarily coordi-
nated by insulin, which suppresses hepatic gluconeogenesis by
reducing the expression of the key gluconeogenic enzymes
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-
phosphatase (G6Pase). Liver insulin resistance, a major factor
in the development of type 2 diabetes, leads to excessive post-
prandial glucose production and abnormal blood glucose levels.
Binding of insulin to its cognate receptor stimulates receptor
tyrosine kinase activity, resulting in the phosphorylation of sev-
eral substrates, including insulin receptor substrate (IRS) pro-
teins (White, 2003). IRS phosphorylation leads to the recruitment
and activation of type 1A phosphatidylinositol (PtdIns) 3-kinase,
which catalyzes the formation of the lipid second messenger
PtdIns(3,4,5)-trisphosphate [PtdIns(3,4,5)P3] at the plasma
membrane. Elevation of PtdIns(3,4,5)P3 levels alters the locali-
zation and induces the activation of several protein kinases, in-
cluding those of the Akt family (also known as protein kinase B).
Loss of Akt2 function in mice results in insulin resistance and im-
paired glucose tolerance due to dysregulated hepatic glucose
production and decreased uptake in skeletal muscle (Cho
et al., 2001), demonstrating its critical role in insulin signaling.
Akt modulates G6Pase and PEPCK expression by suppress-
ing the activity of FOXO1, a member of the forkhead family of
transcription factors (reviewed in Accili and Arden, 2004 andCELL METABOLISM 3, 367–378, MAY 2006 ª2006 ELSEVIER INC. DBarthel et al., 2005). In the absence of insulin stimulation,
FOXO1 is localized to the nucleus and acts in concert with the
peroxisome proliferator-activated receptor-g coactivator 1 a
(PGC-1a) to increase gluconeogenic gene transcription (Puig-
server et al., 2003). Upon insulin stimulation, Akt phosphorylates
FOXO1 at three sites, inducing FOXO1 translocation to the cyto-
plasm and thereby reducing its transcriptional activity. Targeted
expression of a constitutively nuclear FOXO1 mutant to the liver
promotes diabetes in transgenic mice (Nakae et al., 2002). In
contrast, FOXO1 haploinsufficiency restores insulin sensitivity
in mice with defective insulin signaling (Nakae et al., 2002).
Moreover, hepatic expression of a FOXO1 dominant-negative
mutant reduces G6Pase and PEPCK expression and hepatic
glucose output (Altomonte et al., 2003). FOXO1 has also been
shown to mediate insulin-regulated hepatic expression of apoli-
poprotein CIII, a regulator of plasma triglyceride metabolism (Al-
tomonte et al., 2004). These and other studies demonstrate that
FOXO1 serves as a molecular link between insulin and changes
in hepatic gene expression that, when dysregulated, can give
rise to features of type 2 diabetes, including excessive hepatic
glucose output and systemic hypertriglyceridemia.
Here, we have combined a genomics-based functional
screening strategy with quantitative image analysis (also re-
ferred to as high content screening, image cytometry, or ma-
chine vision analysis) to identify novel modulators of FOXO1
subcellular localization. One such factor is the nonreceptor pro-
tein tyrosine phosphatase (PTP)-MEG2 (or PTPN9), which when
overexpressed, results in the nuclear accumulation of FOXO1.
Forced expression of PTP-MEG2 in cell lines and in mouse liverOI 10.1016/j.cmet.2006.03.006 367
A R T I C L EFigure 1. Screen for modulators of FOXO1 subcellu-
lar localization
A) Approximately 4800 human and mouse genes
were individually cotransfected with a GFP-FOXO1
reporter. Plates were imaged using high-throughput
fluorescence microscopy and the average percent-
age of GFP-FOXO1 localized in the nucleus was de-
termined for each gene.
B) Cotransfection of GFP-FOXO1 with selected
cDNAs identified through the genome-scale screen
into U2OS cells. Nuclei are stained with DAPI (blue)
while GFP-FOXO1 is shown in green. Cotransfection
with empty vector pcDNA3 served as a negative con-
trol and constitutively nuclear FOXO1-GFP (AAA) is
also shown. Ectopic expression of cDNAs increased
FOXO1 nuclear localization more than 3.5 standard
deviations from a calculated mean (row 1, column 3
through row 2, column 5), or resulted in further cyto-
plasmic accumulation of the transcription factor (>2
standard deviations; row 3, columns 1–5). The scale
bar represents 20 mm.decreases insulin receptor phosphorylation, while the reduction
of PTP-MEG2 levels increases insulin-mediated suppression of
FOXO1 activity in hepatoma cell lines and dramatically improves
glucose tolerance in diabetic (db/db) mice. These results indi-
cate a novel role for PTP-MEG2 in the negative regulation of
hepatic insulin signaling.
Results
Image-based screen for FOXO1 regulators
To identify novel regulators of FOXO1subcellular localization, ar-
rayed full-length cDNAs from the Mammalian Genome Collec-
tion (Strausberg et al., 1999) were individually cotransfected
with a GFP-FOXO1 reporter construct into U2OS osteosarcoma
cells using a high-throughput methodology (Figure 1A; Chanda
et al., 2003). After a 2 day incubation period, cells were fixed
and stained with the DNA binding dye DAPI. Two sets of images
(one each for theDAPI andGFP fluorophores) were collected us-
ing automated fluorescencemicroscopy and analyzed usingCy-
toShop software (Beckman Coulter) (Harada et al., 2005). Image
segmentation was initially performed upon images obtained
from theDAPI channel. To ensure that only single cells were con-
sidered, all objects within the images which did not conform to
experimentally determined parameters reflecting appropriate
nuclear intensity and nuclear shape were excluded. The cyto-
plasm for each cell was then defined as an annulus of 30 pixels
from the nuclear edge. Imaged GFP-expressing cells were then
associated with their respective nuclei, and the percentage of
FOXO1 localized in the nucleus (FLIN) was determined for each
transfected cell and averaged for each well. Cells that had ex-
treme FLIN values (>95% or <5%) were excluded from the anal-
ysis, since such measurements typically arose from segmenta-
tion or other artifacts (for example, GFP from the cytoplasm of
a neighboring cell intersecting a nontransfected cell). To deter-368mine the effects of each encoded protein upon FOXO1 subcellu-
lar localization, the FLIN values of themiddle 90%of transfected
wells were averaged for each plate and used to define a plate
mean and standard deviation. Subsequently, well activities
were defined in terms of standard deviations from the plate
mean (s level).
In U2OS cells maintained under 10% serum conditions, GFP-
FOXO1 is primarily localized in the cytoplasm but can also be
found in both the cytoplasm and the nucleus in a fraction of
the transfected population (Nakamura et al., 2000, Figure 1B).
GFP-FOXO1 distribution is correlated with its expression levels,
and this heterogeneity results in a median FLIN calculation of
50% in unperturbed cells. For comparison, transfection of a mu-
tant GFP-FOXO1 construct, in which the three Akt phosphoryla-
tion sites are altered to alanine (T24A/S256A/S319A, referred to
as AAA), results in nearly all of the GFP fluorescence colocalizing
with the nucleus (FLIN value of 75%, 11 s, Figure 1B). Cotrans-
fection of GFP-FOXO1 with the lipid phosphatase PTEN, a
known antagonist of PI3K/Akt signaling, results in dephosphor-
ylation of theAkt-responsive residues in FOXO1and a significant
increase in the percentage of GFP-FOXO1 in the nucleus (FLIN
64%, 6s, Figure 1B; Nakamura et al., 2000). In contrast, overex-
pression of Akt1 results in GFP-FOXO1 cytoplasmic localization
(FLIN 40%, 22.5 s, data not shown).
Ectopic expression of 14 genes identified through the screen
was confirmed to induce FOXO1 nuclear localization by >3.5 s,
while ten encoded proteins promoted a decrease in levels of nu-
clear FOXO1 by >2 s under these experimental conditions (Ta-
bles 1 and S1 in the Supplemental Data available with this article
online). Several genes identified in the screen are known to be
associated with the PI3K/Akt signaling pathway. The p85b sub-
unit of PI3 kinase can act as a negative regulator of insulin sig-
naling (Ueki et al., 2002), and its overexpression resulted in the
strongest induction of GFP-FOXO1 nuclear localization (10 s).CELL METABOLISM : MAY 2006
PTP-MEG2 inhibits hepatic insulin signalingTable 1. Regulators of FOXO1 subcellular localization identified through genome-scale functional analysis
Accession Gene Symbol Name
Sigma level
of nuclear
FOXO1 Selected GO Annotations Selected Interpro Domains
BC006796 Pik3r2* phosphatidylinositol 3-kinase,
regulatory subunit, polypeptide 2
(p85 beta)
9.61 insulin receptor signaling pathway
(GO:0008286) phosphatidylinositol
3-kinase activity (GO:0016303)
PI3 kinase, P85 regulatory subunit
(IPR001720)
BC010863 PTPN9/
PTP-MEG2
protein tyrosine phosphatase,
nonreceptor type 9
9.01 protein tyrosine phosphatase
activity (GO:0004725)
Phosphatidylinositol transfer protein-like,
N-terminal (IPR011074);Protein tyrosine
phosphatase, catalytic region
(IPR003595)
BC011286 3100004P22Rik hypothetical protein LOC68035 6.26 nuclear mRNA splicing, via
spliceosome (GO:0000398)
RNA-binding region RNP-1
(RNA recognition motif) (IPR000504)
BC018480 Guca1b guanylate cyclase activator 1B 6.19 Calcium sensitive guanylate
cyclase activator activity
(GO:0008048)
Calcium-binding EF-hand (IPR002048)
BC015180 HOXA3 homeo box A3 6.03 development (GO:0007275);
regulation of transcription,
DNA-dependent (GO:0006355)
Homeobox (IPR001356)
BC005821 PTEN* phosphatase and tensin homolog
(mutated in multiple advanced
cancers 1)
6.00 phosphatidylinositol-3,4,5-
trisphosphate 3-phosphatase
activity (GO:0016314)
Protein tyrosine phosphatase, catalytic
region (IPR003595)
BC010315 Tdg thymine DNA glycosylase 5.91 hydrolase activity (GO:0016787) Uracil-DNA glycosylase superfamily
(IPR005122)
BC006704 Dyrk3 dual-specificity tyrosine-(Y)-
phosphorylation-regulated
kinase 3
4.94 protein serine/threonine kinase
activity (GO:0004674)
Serine/threonine protein kinase
(IPR002290)
BC011211 Mat1a methionine adenosyltransferase I,
alpha
4.91 ATP binding (GO:0005524) S-adenosylmethionine synthetase
(IPR002133)
BC016616 5830417I10Rik hypothetical protein LOC76022 4.47
BC013639 Hoxb13 homeo box B13 4.37 regulation of transcription,
DNA-dependent (GO:0006355)
Homeobox (IPR001356)
BC004793 Pcbp1 poly(rC) binding protein 1 4.04 DNA binding (GO:0003677) KH (IPR004087)
BC008602 PSTPIP1 proline-serine-threonine
phosphatase interacting
protein 1
3.79 endocytosis (GO:0006897) Cdc15/Fes/CIP4 (IPR001060)
BC016509 SCAMP4 secretory carrier membrane
protein
3.61 hydrolase activity (GO:0016787) Cytidine/deoxycytidylate deaminase,
zinc-binding region (IPR002125)
N/A pSG5L Control 0
BC001263 SGK* serum/glucocorticoid-regulated
kinase
22.05 protein serine/threonine kinase
activity (GO:0004674)
Protein kinase (IPR000719)
BC011198 Apoa5 apolipoprotein A-V 22.48 lipid transport (GO:0006869) Apolipoprotein A/E/C3 (IPR009074)
BC000995 SFN* stratifin (14-3-3 sigma) 22.55 protein kinase C inhibitor
activity (GO:0008426)
14-3-3 protein (IPR000308)
BC012035 TLOC1 translocation protein 1 22.98 receptor activity (GO:0004872) Translocation protein Sec62 (IPR004728)
BC010735 EEF1A1 eukaryotic translation elongation
factor 1 alpha 1
23.03 GTPase activity (GO:0003924);
protein biosynthesis (GO:0006412)
EF-Tu/eEF-1alpha/eIF2-gamma,
C-terminal (IPR009001)
BC016618 LCP2 lymphocyte cytosolic protein 2 23.20 transmembrane receptor protein
tyrosine kinase signaling pathway
(GO:0007169)
Sterile alpha motif SAM (IPR001660)
BC011153 Sqrdl sulfide quinone reductase-like
(yeast)
23.36 oxidoreductase activity
(GO:0016491)
FAD-dependent pyridine
nucleotide-disulphide
oxidoreductase (IPR001327)
BC015326 SGKL* serum/glucocorticoid-regulated
kinase-like
23.52 protein amino acid phosphorylation
(GO:0006468)
Protein kinase (IPR000719)
BC003623 YWHAZ* tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase
activation protein (14-3-3 zeta)
23.89 protein domain specific binding
(GO:0019904)
14-3-3 protein (IPR000308)
BC020963 YWHAG* 3-monooxygenase/tryptophan
5-monooxygenase activation
protein, gamma polypeptide
(14-3-3 gamma)
24.13 insulin-like growth factor receptor
binding (GO:0005159); negative
regulation of protein kinase
activity (GO:0006469)
14-3-3 protein (IPR000308)
High-throughput functional analysis revealed that overexpression of these cDNA clones lead to an increase (sigma level > 0) or decrease (sigma level < 0) in the fraction of
GFP-FOXO1 localized to the nucleus, as compared to a negative control (pSG5L). Sigma levels are provided as a function of standard deviations to the mean score of
nonresponders on a plate (see Experimental Procedures). All activities were subsequently reconfirmed in secondary assays. Selected GO annotations and InterPro do-
mains for each encoded protein are also provided, and previously known or inferred regulators of FOXO1 are indicated with an asterisk (*).Conversely, transfection of cDNAs encoding three 14-3-3 pro-
teins (sigma, gamma, and zeta subtypes) increased GFP-
FOXO1 cytoplasmic localization, possibly through direct binding
to phosphorylated FOXO1 (Figure 1B; Brunet et al., 1999). Ex-CELL METABOLISM : MAY 2006pression of the kinase serum/glucocorticoid-regulated kinase
(SGK) also directed FOXO1 to the cytoplasm, an activity previ-
ously shown to be mediated by phosphorylation of FOXO1 at
residues T24 and S319 (Brunet et al., 2001). The kinase SGKL,369
A R T I C L Ewhich is highly homologous to SGK, also increases FOXO1 cy-
toplasmic localization. To our knowledge, the remaining 17
genes (Table 1) that affect FOXO1 nuclear localization have
not previously been associated with PI3K/Akt signaling.
PTP-MEG2 reduces Akt-mediated FOXO1
phosphorylation
To test if the identified proteins regulate FOXO1 cellular distribu-
tion throughmodulation of the PI3K/Akt pathway, cDNAswhose
overexpression resulted in increased nuclear localization of the
transcription factor were cotransfected with FOXO1 in U2OS
cells. Western blot analysis revealed that transfection of several
genes, including PTP-MEG2/PTPN9, reduced phosphorylation
levels of FOXO1 at S256, a residue which is targeted by Akt ki-
nase activity (Figures 2A and S1A, data not shown). Consistent
with the observed inhibition of Akt activity, phosphorylation of
endogenous Akt at S473, a PDK2 phosphorylation site, was
also reduced subsequent to transfection of PTP-MEG2 (Fig-
ure 2A), suggesting that expression of PTP-MEG2 reduces
PtdIns(3,4,5)P3 concentration at the plasma membrane.
PTP-MEG2 was one of the most potent regulators of FOXO1
localization identified through the large-scale screen (Table 1);
therefore this phosphatase was chosen for further study. To
confirm that the observed role of PTP-MEG2was not due to non-
specific activities associated with the overexpression of a phos-
phatase, we monitored FOXO1 subcellular localization after
cotransfection with two other PTPs. The ectopic expression of
PTP-MEG1 and TC-PTP (transcript variant 2) resulted in a mar-
ginal increase of GFP-FOXO1 in the nucleus (2.1% and 7%, re-
spectively), whereas the introduction of PTP-MEG2 resulted in
a 62% increase in FOXO1 nuclear localization (Table S1). We
next constructed mutants of PTP-MEG2 which disrupted either
the phosphatase or conserved Sec14p homology domains in
the protein. We ectopically expressed wild-type PTP-MEG2
and these mutants in U2OS cells and quantitated the effect on
FOXO1 localization. While PTP-MEG2 overexpression resulted
in a 71% FLIN value, the effect of the catalytically inactive PTP-
MEG2 (C515S) mutant was comparable to activities observed
with negative controls (54% FLIN, Figure 2B). In addition, ex-
pression of a truncated PTP-MEG2, containing only the catalytic
domain, did not result in a significant increase in FOXO1 translo-
cation (57% FLIN; Figure 2B). These results indicate that both
phosphatase activity and the Sec14p homology domain are re-
quired for PTP-MEG2 to potentiate FOXO1 nuclear localization.
PTP-MEG2 has been previously reported to promote secre-
tory vesicle fusion (Wang et al., 2002, 2005; Huynh et al.,
2003). To investigate whether the observed effects of PTP-
MEG2 on FOXO1 subcellular localization could be due to its abil-
ity to regulate cellular secretion processes, we cotransfected
a plasmid encoding secreted alkaline phosphatase (SEAP) along
with plasmids encoding wild-type or catalytically inactive PTP-
MEG2 into U2OS cells. Expression of neither protein resulted
in a reduction of SEAP concentrations in the culture media, indi-
cating that the effects of PTP-MEG2 upon FOXO1 signaling are
likely independent of global effects upon secretory pathways
(Figure S1B).
Ectopic expression of PTP-MEG2 antagonizes
insulin signaling
To determine if ectopic expression of the tyrosine phosphatase
PTP-MEG2 would affect the transcription of hepatic insulin-re-370sponsive genes, PTP-MEG2was cotransfected with a construct
containing G6Pase enhancer elements upstream of a luciferase
reporter gene into HepG2 cells. Wild-type PTP-MEG2 expres-
sion attenuated insulin-mediated repression of G6Pase expres-
sion (Figure 2C), while the catalytically inactive PTP-MEG2
(C515S) did not. Insulin treatment had no effect on the activity
of a mutant G6Pase reporter construct that is unresponsive to
FOXO1; the activity of the mutant construct was also unper-
turbed by the expression of PTP-MEG2. Moreover, adenovi-
ral-mediated PTP-MEG2 overexpression in primary rat hepato-
cytes blocked insulin-stimulated repression of endogenous
PEPCK expression as monitored by quantitative polymerase
chain reaction (PCR) (Figure 2D), confirming the effect of PTP-
MEG2 in a physiologically relevant context. Taken together,
these data demonstrate that PTP-MEG2 activity opposes insu-
lin-mediated repression of gluconeogenic gene transcription.
To explore the molecular basis of PTP-MEG2 activity respon-
sible for this observed antagonism of insulin signaling, PTP-
MEG2 was overexpressed in HEK-293A cells which were
serum-starved and treated with insulin-like growth factor-1
(IGF-1). Immunoprecipitation-mass spectrometry analysis of
PTP-MEG2-transfected and control lysates using an anti-phos-
photyrosine antibody (Salomon et al., 2003) revealed decreased
levels of IRS-1 and IGF-1 receptor tyrosine phosphorylation in
cells receiving exogenous PTP-MEG2 (data not shown). To ver-
ify that PTP-MEG2 activity results in the dephosphorylation of
insulin/IGF1 receptors, a vector control, PTP-MEG2, and PTP-
MEG2 (C515S) were transiently transfected into HEK-293A
followed by serum starvation and insulin treatment. Immunopre-
cipitation of the insulin receptor b subunit followed by immuno-
blotting and probing with the anti-phosphotyrosine antibody
4G10 confirmed that PTP-MEG2 overexpression reduces in-
sulin-stimulated insulin receptor phosphorylation (Figure 2E).
Immunoblots of lysates from PTP-MEG2-transfected cells
reveal that PTP-MEG2 expression reduces phosphorylation at
Tyr1162/1163 (Figures 2F and S2A), which is required for its
kinase activity (Ellis et al., 1986). Similar results were obtained
when we assessed the effects of PTP-MEG2 expression upon
IGF stimulation of insulin receptor autophosphorylation or IGF-
mediated phosphorylation of the InsR substrate IRS1 (Figures
S2B and S2C). These data implicate PTP-MEG2 as an antago-
nist of insulin receptor catalytic activity.
Reduction in PTP-MEG2 expression enhances
insulin action
To assess whether endogenous PTP-MEG2 activity attenuates
insulin receptor signaling, RNA interference was used to reduce
PTP-MEG2 expression in the hepatocellular carcinoma HepG2
cell line. Transfection of a 21-mer duplex RNA oligonucleotide
directed against human PTP-MEG2, as well as a mixture of
four oligonucleotides (Smartpool), reduced PTP-MEG2 protein
levels by approximately 55% and 40%, respectively (Figures
3A and S3). Decreased PTP-MEG2 levels resulted in enhance-
ment of insulin receptor autophosphorylation in response to in-
sulin (Figures 3A and S3). In addition, PTP-MEG2 inhibition also
augmented the phosphorylation of Akt in response to insulin,
consistent with an increase in levels of insulin signaling
(Figure 3A). These results confirm that decreased PTP-MEG2
potentiates insulin signaling in insulin-responsive cell types.
Since reduction of PTP-MEG2 protein levels increases insulin-
mediated insulin receptor phosphorylation, loss of PTP-MEG2CELL METABOLISM : MAY 2006
PTP-MEG2 inhibits hepatic insulin signalingFigure 2. PTP-MEG2 modulates insulin signaling in cultured cells
A) HEK-293A cells were cotransfected with a vector control, PTP-MEG2, or catalytically inactive PTP-MEG2 (C515S) with GFP and FOXO1. After fluorescence-activated
cell sorting, cells were grown in 10% FBS/DMEM and lysates were analyzed by immunoblot. PTP-MEG2 overexpression reduced both phosphorylation of FOXO1 at
Ser256 (Akt phosphorylation site) and Akt at S473.
B)Catalytic activity and Sec14p homology domain are required for PTP-MEG2 induction of FOXO1 nuclear translocation. Control vector pcDNA3, PTP-MEG2, PTP-MEG2
(C515S), or PTP-MEG2 catalytic subunit (DSec14) were cotransfected with GFP-FOXO1. Images were acquired as in Figure 1. The scale bar represents 20 mm.
C) PTP-MEG2 overexpression alters the transcriptional response of a glucose-6-phosphatase reporter construct in HepG2 cells and is dependent on FOXO1 binding sites.
Insulin treatment reduces the G6Pase luciferase reporter activity, but this effect is reversed by wild-type PTP-MEG2. The catalytically inactive PTP-MEG2 (C515S) mutant
has no effect. A reporter construct in which the FOXO1 binding sites are mutated shows no response to either insulin treatment or PTP-MEG2 expression.
D) PTP-MEG2 blunts insulin-dependent inhibition of gluconeogenic gene expression. Quantitative PCR analysis of PEPCK transcripts was performed with RNA from rat
primary hepatocytes infected with either GFP virus or PTP-MEG2 expression virus. For insulin treatment, cells were starved overnight, and 100 nM insulin was added
for 8 hr.
E) PTP-MEG2 overexpression results in a decrease in insulin receptor tyrosine phosphorylation. HEK-293A cells were transfected with a vector control, PTP-MEG2, or
PTP-MEG2 (C515S) and serum starved. Cells were treated with insulin (10 nM for 30 min) and then lysed. Insulin receptor was immunoprecipitated and immunoblots
were probed with the anti-phosphotyrosine antibody 4G10.
F) PTP-MEG2 expression induces dephosphorylation of insulin receptor residues Y1162/Y1163. HEK-293A cells were transfected with PTP-MEG2 or a vector control,
serum starved, and treated with insulin (20 nM for 30 min). Lysates were prepared and equal quantities of total protein were loaded on to an SDS-PAGE gel for immunoblot
analysis with the anti-InsR pY1162/1163 antibody. Levels of insulin receptor and b-actin were measured as controls for loading. Error bars represent standard deviations
from the experimental mean of at least three independent experiments.CELL METABOLISM : MAY 2006 371
A R T I C L EFigure 3. Reduction of PTP-MEG2 expression via RNA interference potentiates
insulin activity in hepatoma cell lines
A)HumanHepG2 cells were transfectedwith an RNAduplex targeting PTP-MEG2,
an RNA duplex against a control (mouse Trb3) sequence that does not target any
human genes, or a mixture of four RNA duplexes against PTP-MEG2 (Dharmacon
Smartpool). After serum starvation and insulin treatment (3 nM for 30 min), lysates
were prepared, and immunoblots were probed with the antibodies shown.
B) Reduction of PTP-MEG2 expression potentiates insulin repression of G6Pase
expression in H4IIE cells. G6Pase-luc/H4IIE cells were infected with either PTP-
MEG2 or control shRNA adenoviruses. Efficacy of RNAi treatment was measured
by Western blot analysis with antibodies specific for PTP-MEG2 and b-actin (in-
set). Cells were serum starved and treated with dexamethasone (25 mM) and indi-
cated concentrations of insulin. Activities for each replicate were normalized
against PBS-treated cells.
p values were determined using two-sample assuming equal variances t test.
Each data point represents the mean (6SD) of at least three independent
experiments.372function would be expected to enhance insulin’s suppression of
gluconeogenic target genes in liver cell lines. To test this hypoth-
esis, an adenovirus encoding a short hairpin RNA targeted
against the rodent PTP-MEG2 sequence (Ad-MEG2 shRNA)
was generated. H4IIE rat hepatoma cells, harboring an inte-
grated luciferase reporter linked to G6Pase enhancer elements,
were infected with the Ad-MEG2 shRNA. Infection with Ad-
MEG2 shRNA resulted in a 50% reduction of PTP-MEG2 protein
expression, as compared to control-infected cells (Figure 3B,
inset). Decreased PTP-MEG2 expression resulted in approxi-
mately a 2-fold increase in insulin responsiveness (Control IC50
1.05 nM, MEG2 RNAi IC50 0.55 nM), as measured by the dose
response of G6Pase-luc reporter activity (Figure 3B).
Increased PTP-MEG2 expression in liver suppresses
insulin signaling
To test the activity of PTP-MEG2 on insulin action in vivo, we
constructed adenoviruses that express PTP-MEG2 or GFP as
a negative control. Following tail-vein injection into mice, the
PTP-MEG2 adenovirus conferred increased expression of
PTP-MEG2 in the liver (Figure 4A). No differences in basal blood
glucose concentrations could be detected between the GFP
and PTP-MEG2-infected mice (Figure S4A). To test their re-
sponse to insulin, infected mice were injected with a bolus of ei-
ther insulin or PBS after a 4 hr fast, and protein extracts from
liver were examined by Western blot analysis. PTP-MEG2 over-
expression decreased insulin receptor, GSK3-b, and Akt phos-
phorylation (Figures 4A, S4B, and S4C) after insulin stimulation.
To assess the effect of PTP-MEG2 expression on glucose ho-
meostasis, we conducted glucose tolerance tests (GTT) on
PTP-MEG2 and GFP-expressing mice. During the GTT, PTP-
MEG2-mice had consistently higher levels of blood glucose
compared to GFP-injected mice, particularly at the 15 min (p <
0.04) and 30 min (p < 0.02) time points after glucose injection
(Figure 4B). Furthermore, the behavior of blood glucose levels
during insulin tolerance tests (ITT) indicated that forced hepatic
PTP-MEG2 expression results in decreased insulin sensitivity
(Figure 4C). These results demonstrate that elevated levels of
PTP-MEG2 expression suppress insulin signaling in the liver
and may contribute to insulin resistance.
PTP-MEG2 expression in the liver increases
during fasting
We next investigated whether PTP-MEG2 expression levels in
mouse liver were affected by fasting and refeeding conditions.
Adult male C57Bl/6 mice (n = 6 per group) were fasted for 16 hr,
or fasted for 24 hr and refed for another 24 hr. Total RNA was
prepared from liver and PTP-MEG2 and phosphoenolpyruvate
carboxykinase (PEPCK) expression levels were measured us-
ing quantitative RT-PCR (Figure 4D). As expected, PEPCK ex-
pression increased 141% during fasting (p < 0.001) and re-
turned to normal after refeeding. PTP-MEG2 expression
levels also increased in the livers of fasted mice (33%, p <
0.001), but were 21% lower in refed mice (p < 0.001) compared
to fed mice. These data reveal that PTP-MEG2 expression is in-
versely related to insulin levels, suggesting that PTP-MEG2 is
transcriptionally responsive to systemic alterations of insulin
concentration.CELL METABOLISM : MAY 2006
PTP-MEG2 inhibits hepatic insulin signalingFigure 4. Transgenic PTP-MEG2 inhibits suppression of hepatic glucose output
A) PTP-MEG2 expression inhibits insulin signaling. Western blot analysis was performed with protein extracts from mouse liver infected with either GFP virus or MEG2
expression virus. Livers were collected after a bolus of insulin or PBS injection. Levels of PTP-MEG2 and total and phosphorylated forms Akt, Gsk3b and Insulin Receptor
(IR) are shown.
B) PTP-MEG2 overexpression in mouse liver leads to impaired glucose tolerance. Mice injected with either GFP control virus or PTP-MEG2 expression virus were used for
glucose tolerance test.
C) Ectopic expression of PTP-MEG2 induces insulin resistance. Mice infected with either control or PTP-MEG2 adenovirus were used for insulin tolerance test.
D) PTP-MEG2 expression is elevated under fasting conditions. Quantitative PCR analysis of PTP-MEG2 and PEPCK transcripts was done with RNA from livers of fed,
fasted (16 hr), or refed adult male mice (n = 6). Relative PTP-MEG2 or PEPCK expression was normalized to that of 36B4 ribosomal protein RNA in each sample. PTP-
MEG2 levels were significantly increased (p < 0.001) during fasting when compared to refed samples.
p values were calculated with the Student’s t test and are indicated. Each point represents the mean (6SD) of at least three independent experiments.Hepatic silencing of PTP-MEG2 improves insulin
sensitivity in db/db mice
To ascertain whether modulation of PTP-MEG2 activity can re-
store insulin sensitivity and glycemic regulation in diabeticmice,
we introduced adenovirus encoding a siRNA-hairpin directed
against PTP-MEG2 to the liver of these animals. After fasting,
mice were injected with insulin, and livers were harvested and
analyzed by Western blot analysis. When compared to liver ex-
tracts from nonspecific RNAi-treated mice, hepatic reduction of
PTP-MEG2 levels resulted in an increase in insulin signaling as
assessed by the phosphorylation status of insulin receptor and
Akt (Figure 5A, S5A, and S5B). Correspondingly, the insulin-CELL METABOLISM : MAY 2006stimulated transcriptional repression of the gluconeogenic
genes PGC-1a and G6Pase was also markedly augmented in
these animals (Figure 5B). We next performed glucose tolerance
tests (GTT) on db/db mice injected with adenovirus encoding
MEG2 or control siRNAs. These studies reveal that attenuation
of hepatic PTP-MEG2 expression in db/dbmice leads to in a sig-
nificant reduction in both the amplitude and duration of elevated
blood sugar levels (Figure 5C). Finally, we measured blood glu-
cose levels in the MEG2 and control siRNA-infected db/dbmice
either under fasted conditions or an ad libitum feeding regimen.
Reduction of PTP-MEG2 resulted in a decrease in blood glucose
levels during fasting and lead to a significant reversal of373
A R T I C L EFigure 5. Reduction of hepatic PTP-MEG2 levels in
diabetic mice results in insulin sensitization
A) Silencing of PTP-MEG2 in the liver of db/db mice
leads to an increased response to insulin. Livers
were collected from db/db mice infected with either
an siRNA targeting PTP-MEG2 (MEG2i) or a control
sequence (US) after bolus injection of insulin or
PBS. Western blot analysis was performed with
liver-derived protein extracts to determine levels of
PTP-MEG and total and phosphorylated forms of
Akt and Insulin receptor (IR).
B) Reduction of PTP-MEG2 levels potentiates insu-
lin-induced repression of gluconeogenic target
genes. RNA was collection from db/db mouse livers
as described in (A), and quantitative RT-PCR was
performed using primer and probe sets specific for
PGC-1a, G6Pase, and PTP-MEG2. mRNA levels
were normalized to an internal control, and values
for the control siRNA-treated mice were set to 1.
C) Improved glucose clearance mediated by sup-
pression of PTP-MEG2. Mice injected with either
control virus (US) or PTP-MEG2 (MEG2i) siRNA virus
were used for glucose tolerance test.
D) Hepatic silencing of PTP-MEG reverses hypergly-
cemia. Ad lib or 4 hr fasting blood glucose levels
were measured in db/db mice injected with US/
MEG2 RNAi adenovirus.
p values were calculated with the Student’s t test and
are indicated. Each point represents the mean (6SD)
of at least three independent experiments.hyperglycemia under ad lib feeding (Figure 5D). Taken together,
these data indicate that the antagonism of PTP-MEG2 activity
can restore insulin sensitivity and improve glycemic regulation
in diabetic mice.
Discussion
We have profiled a library containing approximately 4800 full-
length human and mouse cDNAs to identify novel regulators of
the pleiotropic transcription factor FOXO1. The library was
screened in an arrayed format, which allowed us to individually
interrogate the activity of each encoded protein within the ma-
trix. To monitor the cellular distribution of FOXO1, we employed
an automated fluorescence microscopy platform in conjunction
with pattern recognition and image analysis software. This en-
abled robust and accurate assessment of the fraction of
FOXO1 localized to the nucleus (FLIN) in over 150,000 acquired
images at the level of individually transfected cells. This repre-
sents a generally applicable methodology towards the ge-
nome-wide analyses of factors that regulate protein subcellular
localization in response to extracellular stimuli.
The FOXO1 transcriptional program governs a number of dis-
tinct cellular processes, including oncogenesis, metabolic func-
tion, differentiation, and survival (Accili and Arden, 2004 and
Barthel et al., 2005). In response to various extracellular stimuli,
FOXO1 is phosphorylated by Akt andSGK and subsequently se-
questered in the cytoplasm, thus abolishing forkhead target
gene expression. In addition to Akt signaling, several other path-
ways can regulate FOXO activity. For example, cellular stress in-
duces acetylation of FOXO proteins by p300/CBP-associated
factor PCAF, while expression of the nutrient sensing HDAC
Sirt1 results in FOXO deacetylation (Brunet et al., 2004; Motta
et al., 2004). Although several genes identified in the screen374have been previously implicated in the regulation of FOXO1,
this functional assay also revealed seventeen novel mediators
of FOXO1 subcellular localization in U2OS cells. Not surpris-
ingly, these encoded proteins belong to a broad range of func-
tional classes: kinases and other phosphorylation-related pro-
teins, transcription factors, enzymes, trafficking proteins, lipid
binding proteins, as well as proteins without assigned function.
Since the genome-scale assay was executed under undefined
growth factor conditions (10% serum), it is unclear if the proteins
elucidated in the screen are influencing FOXO1 localization in
U2OS cells through themodulation of signaling induced by insu-
lin or other growth factors contained in the media. Further study
will be required to characterize the functional role of gene prod-
ucts identified through this approach in the modulation of
FOXO1 activity.
The screen revealed a previously unidentified role for the non-
receptor protein tyrosine phosphatase PTP-MEG2 as potent in-
ducer of FOXO1 nuclear localization. Interestingly, PTP-MEG2
has been previously implicated in the regulation of homotypic
vesicle fusion in hematopoetic cell types (i.e., mast cells, T cells,
and granulocytes; Wang et al., 2002). Furthermore, T lympho-
cytes derived from mice lacking PTP-MEG2 displayed defects
in interleukin 2 secretion (Wang et al., 2005). The phosphatase
regulates the secretory pathway through dephosphorylation of
the fusion protein N-ethylmaleimide-sensitive factor (NSF;
Huynh et al., 2004). However, we were not able to detect any
effects of PTP-MEG2 overexpression upon global secretory
mechanisms in U2OS (osteosarcoma) cells (Figure S1B). We
speculate that the regulation of vesicle fusion events by PTP-
MEG2 may be restricted to certain cell types, and the phospha-
tase possesses pleiotropic activities that are likely dependent
on tissue-specific expression of its substrates, such as NSF
(Su et al., 2004; http://symatlas.gnf.org). We further concludeCELL METABOLISM : MAY 2006
PTP-MEG2 inhibits hepatic insulin signalingthat the observed effects of PTP-MEG2 upon glucose homeo-
stasis are likely due to direct modulation of insulin signaling
and are exclusive of its previously described role in vesicle fu-
sion. Since FOXO1 has an essential role in the control of liver
glucose production, we further characterized PTP-MEG2 activ-
ity within the context of insulin signal transduction, although it is
possible that the phosphatase may also act as a negative regu-
lator of other growth factor pathways. Ectopic PTP-MEG2 ex-
pression blunts insulin-mediated transcriptional repression of
gluconeogenic genes. Furthermore, overexpression of PTP-
MEG2, both in vitro and in vivo, results in a coordinate reduction
in phosphorylation levels of Akt, IRS-1, and the insulin receptor
(InsR) proteins. These results suggest that PTP-MEG2 regulates
insulin signal transduction by attenuating the activation of the in-
sulin receptor but does not distinguish between a role for PTP-
MEG2 regulating InsR activity through direct dephosphorylation
of the receptor or by the modulation of a secondary, yet uniden-
tified, protein. The immediate substrate of PTP-MEG2 phospha-
tase activity is currently under investigation. Conversely, reduc-
tion of PTP-MEG2 expression levels with RNAi-targeting
sequences in hepatoma cell lines augments the cellular re-
sponse to insulin, and silencing PTP-MEG2 in the livers of dia-
betic (db/db) mice resulted in a reversal of insulin resistance
and hyperglycemia. These results indicate that PTP-MEG2 reg-
ulates glucose homeostasis and hepatic insulin action through
the modulation of insulin receptor signaling.
Several PTPs have been previously implicated in the inhibition
of insulin signal transduction, most notably PTP-1b (see Asante-
Appiah and Kennedy, 2003 for a review). PTP-1b2/2 mice have
improved insulin sensitivity compared to wild-type controls
and are resistant toweight gainwhen fed a high-fat diet (Elchebly
et al., 1999; Klaman et al., 2000). PTP-1b is localized to the cyto-
plasmic surface of the endoplasmic reticulum, and dephosphor-
ylates receptor tyrosine kinases after receptor endocytosis (Haj
et al., 2002). The roles of other protein tyrosine phosphatases
(PTPs) in insulin signaling are more complex. Overexpression
of the transmembrane PTP leukocyte antigen-related phospha-
tase (LAR) in muscle results in whole-body insulin resistance
(Zabolotny et al., 2001), and LAR-deficient mice have low insulin
and glucose levels (Ren et al., 1998). However, LAR2/2mice are
resistant to insulin-mediated suppression of hepatic glucose
output (Ren et al., 1998). TCPTP, which is closely related to
PTP-1b, has also been reported to have insulin receptor phos-
phatase activity (Galic et al., 2003). Interestingly, recent studies
of insulin receptor activation in PTP-1b2/2 and TCP-TP2/2
mouse embryo fibroblasts suggest that even these closely re-
lated PTPs have nonoverlapping phosphatase activities since
insulin receptor dephosphorylation occurs with distinct time
courses (Galic et al., 2005).
PTPs are a diverse enzyme family with at least 107 members
in the human genome (Alonso et al., 2004). Of these, only PTP-
MEG2 possesses a 250 amino acid lipid binding domain that is
homologous to Sec14p, a yeast protein with phosphatidylinosi-
tol (PtdIns) transferase activity. Our overexpression analysis in-
dicates that the Sec14p homology domain is required for PTP-
MEG2-mediated FOXO1 nuclear translocation in U2OS cells
(Figure 2B). Biochemical and colocalization studies have indi-
cated that the Sec14p domain in PTP-MEG2 binds to several
phosphoinositides, including Ptd(3,5)P2, Ptd(4,5)P2, and
Ptd(3,4,5)P3 (Huynh et al., 2003; Kruger et al., 2002), or possibly
to phosphatidylserine (Zhao et al., 2003). A number of phospha-CELL METABOLISM : MAY 2006tidylinositol kinases and phosphatases are involved in various
stages of insulin signaling and receptor tyrosine kinase process-
ing, including p110a and PI3-K-C2a (Brown et al., 1999), gener-
ating signaling intermediates such as Ptd(3,4,5)P3, Ptd(3)P, and
Ptd(3,5)P2. Interestingly, Ptd(4,5)P2 and Ptd(3,4,5)P3 have been
reported to stimulate the phosphatase activity of PTP-MEG2 in
vitro (Kruger et al., 2002). Thus, the observed regulation of insu-
lin receptor activation and hepatic glucose production by PTP-
MEG2 may involve phosphatidylinositol products synthesized
in response to insulin receptor signaling. Taken together, these
results further define the regulation of insulin signaling in the liver
and suggest that pharmacological targeting of PTP-MEG2 may
be a potential strategy for the treatment of type 2 diabetes.
Experimental procedures
High-throughput transfection and imaging
High-throughput (retro)transfections of 4800 human and mouse genes from
the Mammalian Genome Collection (Strausberg et al., 1999) were carried out
as described (Chanda et al., 2003; http://function.gnf.org). In brief, 20 ml mix-
ture of FuGENE 6 (Roche) and GFP-FOXO1 in pcDNA3 (20 ng/well, kindly
provided by Professor W.R. Sellers) in DMEM medium (Invitrogen) was
added to prespotted 384-well black, clear-bottom plates (Greiner) containing
62.5 ng of plasmid DNA per well. After a 30 min incubation, approximately
2000 U2OS cells (ATCC) in 30 ml of DMEM supplemented with 16% FBS (In-
vitrogen) and 1.6 mM glutamine (Invitrogen) were added to each well. Cells
were grown for 60 hr at 37ºC in 5% CO2. Cells were washed with PBS in
an EMBLA plate washer (Molecular Devices) and fixed with 4% paraformal-
dehyde in PBS. Nuclei were stained with 40,6-diamidino-2-phenylindole (200
nM; Molecular Probes) in 0.3% TritonX-100/PBS for 30 min and washed with
PBS. Cells were imaged on an IC100 (Beckman) automated inverted fluores-
cence microscope (Nikon TE300 with a Cohu video camera) with a 103/0.5
objective (Nikon). Sixteen images were collected per well in two channels us-
ing filters appropriate for DAPI and GFP fluorophores. Image analysis was
performed with CytoShop software (Beckman). After images were shade-
corrected and background-subtracted, objects were extracted and single
cells defined using geometric and total fluorescence parameters in the
DAPI channel. Transfected cells were identified based on total GFP fluores-
cence, and the fractional fluorescence in the nucleus (FLIN value) was deter-
mined for all GFP-positive cells. FLIN values were averaged for each well, ex-
cluding wells with less than eight GFP-positive cells. The number of standard
deviations from themean (s value) for each genewas calculated as described
in themain text. Images in Figure 1were acquired on aNikon TE2000 inverted
fluorescence microscope using a 403 objective and processed using Meta-
Morph software (Universal Imaging). Small fluorescent aggregates in the
DAPI channel (resulting from DNA precipitates) were removed via image
processing for clarity. Percentages of cells with cytoplasmic, mixed, and
nuclear GFP-FOXO1 reported in Table S1 were based on counts of >100
fluorescent cells (GFP-FOXO1 fluorescence > 2-fold over background).
Plasmids
hG6Pase (-1227/+57)Luc construct was described previously (Ayala et al.,
1999). FOXO1binding sites at2186 and2172were disrupted by introduction
of point mutations in hG6Pase (21227/+57) Luc construct as reported (Ayala
et al., 1999). To generate the pU6-MEG2 RNAi construct, palindromic se-
quences corresponding to nucleotides 469–490 from the mouse MEG2 cod-
ing sequence (50-GGGTCTAATTATGCCAACTTTG) were linked to human U6
promoter in the pBluescript KS vector (Strategene). For a negative control,
pU6-US construct, an oligonucleotide that does not match with any known
gene (50-GGCATTACAGTATCGATCAGA-30) was used. The catalytically inac-
tive PTP-MEG2 (C515S) mutant was constructed using the QuikChange site-
directed mutagenesis kit following the manufacturer’s instructions using the
oligos 50-CACCCATTGTGGTCCATAGCAGTGCAGGCATTG-30and 50-CAAT
GCCTGCACTGCTATGGACCACAATGGGTG-30. The PTP-MEG2 catalytic
subunit fragment was obtained using PCR with the oligos 50-CCGGAATTC
GCCGCCAGCCATGACCATCCAAGAGTTGGTGG-30 and 50-ATGCCGCTC
GAGTTACTGACTCTCCACGGCCAG-30 and subcloned into the EcoRI and
XhoI sites in pcDNA3 (Invitrogen).375
A R T I C L ESecreted alkaline phosphatase assay
Secreted alkaline phosphatase (SEAP) assay was performed according
to manufacturer’s instructions (Great EscAPe reporter system, BD Biosci-
ences). U2OS cells were transfected with amix of pSEAP-control (BD Biosci-
ences, 10 ng), pGL3 control (Promega, 20 ng) and gene-of-interest (45 ng)
per well in a 384-well plate with FuGENE6 as the transfection reagent. 40
hr after transfection, cells were washed with growth medium and treated
with Brefeldin A (1.5 mM, Sigma-Aldrich), ethanol, or no stimulus (for PTP-
MEG2, PTP-MEG2[C515S], and pcDNA3 transfections) for 4.5 hr. Superna-
tant was removed and SEAP activity was determined using a chemilumines-
cent substrate. Background signal (no pSEAP-control transfected) was sub-
tracted from all signals. For normalization, cells were washed with growth
medium, and luciferase signal was read using Bright Glo (Promega).
G6Pase reporter transient transfection assays
Human hepatoma HepG2 cells were maintained with Ham’s F12 medium
supplemented with 10% FBS (Invitrogen). For transfection, Fugene 6 reagent
was used according to the manufacturer’s instructions. Each transfection
was performed with 50 ng of luciferase construct, 25 ng of b galactosidase
expression plasmid, and 25 ng each of expression vector for wt PTP-
MEG2 or PTP-MEG2 (C515S). If necessary, the empty vector pcDNA3 (Invi-
trogen) was used to maintain a constant amount of DNA for each transfec-
tion. Cells were treated with serum free media +/2 100 nM insulin (Sigma)
for 16 hr and were harvested for luciferase assays. The luciferase activity
was normalized to b galactosidase activity.
Recombinant adenoviruses
Adenoviruses expressing GFP only or nonspecific RNAi control were de-
scribed previously (Koo et al., 2004). Adenoviruses for MEG2 or MEG2
RNAi were generated by homologous recombination as described (Koo
et al., 2004). The virus contained the cDNA encoding GFP under the control
of CMV promoter for monitoring the infection efficiency. For animal experi-
ments, viruses were purified by CsCl method and dialyzed against PBS
buffer containing 10% glycerol before the injection.
Culture of primary hepatocytes
Rat primary hepatocytes were prepared from 200–300 g Sprague-Dawley
rats by collagenase perfusion method as described previously (Koo et al.,
2004). 13 106 cells were plated in 6-well plates with medium 199 (Invitrogen)
supplemented with 10% FBS, 10 units/ml penicillin, 10 mg/ml streptomycin,
and 10 nM dexamethasone for 3–6 hr. After attachment, cells were infected
with adenoviruses expressing either GFP alone or GFP and MEG2 for 16 hr.
Subsequently, cells were maintained in medium 199 without FBS and dexa-
methasone for 8 hr and treated with 100 nM insulin for 16 hr.
Quantitative PCR
Total RNA from primary hepatocytes was extracted using RNeasy mini-kit
(Qiagen). 500 ng (for primary hepatocytes) of total RNA was used for gener-
ating cDNA with Superscript II enzyme (Invitrogen). cDNAs were analyzed by
quantitative PCR using SYBR green PCR kit and an ABIPRISM 7700 Se-
quence detector (Perkin Elmer). All PCR data was normalized to ribosomal
L32 expression in the corresponding sample.
Insulin receptor pulldown and anti-phosphotyrosine analysis
HEK-293A cells (Invitrogen) cultured in 10% FBS/DMEM/glutamine were
transiently transfected with an empty vector, PTP-MEG2, or PTP-MEG2
(C515) using Effectene transfection reagent (Qiagen). After 2 days, cells
were washed with PBS and serum starved in DMEM for 24 hr. Cells were
treated with bovine insulin (Sigma) at 10 nM concentration for 30 min. Cells
were washed with cold TBS and lysed in 1% triton X-100 in TBS with
EDTA (1 mM), protease inhibitors (Roche), sodium fluoride (1 mM) and perva-
nadate (1 mM), and centrifuged at 20,8003 g. Insulin receptor was immuno-
precipitated from the supernatant with anti-insulin receptor b (Upstate Bio-
technologies) overnight followed by binding to Protein G resin (Pierce).
Resin was washed thoroughly and samples for electrophoresis were pre-
pared by boiling in 33 SDS loading buffer. After SDS-PAGE electrophoresis,
proteins were transferred to 0.2 mmnitrocellulose membrane (Schleicher and
Schuell) and probed with anti-phosphotyrosine antibody 4G10 (Upstate) or
anti-insulin receptor b.376Transient overexpression and immunoblot analysis
HEK-293A cells were transfected with an empty vector control or PTP-MEG2
in 35 mm cell culture dishes. After 48 hr, cells were serum starved for 24 hr
and treated with of insulin (20 nM, Sigma) or various concentrations IGF-1
(Sigma). Lysates were prepared as described above, protein concentrations
were determined, and equal quantities of protein were loaded in each lane for
SDS-PAGE and transfered to nitrocellulose. Blots were probedwith anti-InsR
phospho-Tyr1162/1163 (EMD Biosciences), anti-InsR b (Santa Cruz), or anti-
b-actin (Sigma). The blot shown in Figures 2A and S1Awere probedwith anti-
FOXO1 phospho-Ser256 (Cell Signaling #9461) and anti-FOXO1 (Cell Signal-
ing #9462). For loading control analysis, blots were stripped with 2% SDS in
62.5mMTris (pH 6.8) with 100mM b-mercaptoethanol for 25min at 56ºC and
room temperature for 25 min. After washing and blocking, blots were re-
probed with antibodies for total protein levels.
Small inhibitor RNA suppression analysis
HepG2 cells were cultured in MEM-a (Cellgro) supplemented with 10% FBS
and glutamine at 37ºC and 5% CO2. Cells were plated in 35 mm dishes and
transfected with small inhibitor RNA (siRNA) oligos mixed with Lipofectamine
2000 (Invitrogen) following the manufacturer’s protocol. siRNA sequences
were: MEG2 siRNA 50-GCAUUUCCAGCUCGUUUGA-30; mouse Trb3 siRNA
50-CGAGUGAGAGAUGAGCCUG-30 (Du et al., 2003); MEG2 smartpool:
Dharmacon M-008832-00. After 48 hr, cells were washed with PBS and se-
rum starved in MEM-a/glutamine for 24 hr. Cells were treated with insulin
(3 nM) for 30 min and lysed as described above. Lysates were analyzed by
Western blot as described above. PTP-MEG2 levels were probed with a rab-
bit polyclonal antibody 1489B raised against the peptide sequence RPDMA-
PELTPEEE conjugated to keyhole limpet hemocyanin (Imgenex). Akt phos-
phorylation was examined using anti-Akt (phospho-S473) and anti-Akt (Cell
Signaling #9271 and #9272, respectively).
Short hairpin RNA-mediated reduction of PTP-MEG2 expression
PTP-MEG2 RNAi adenovirus and a control RNAi adenovirus were used to in-
fect glucose-6-phosphatase promoter-luciferase stable H4IIE cells (kind gift
from N. Gekakis) in 10% FBS/DMEM with glutamine. After 48 hr, cells were
serum starved in DMEM with glutamine for 24 hr. Cells were treated with
25 mM dexamethasone (Sigma) and various concentrations of insulin for 24
hr. Luciferase signals were read by the addition of BrightGlo reagent (Prom-
ega) and read on an Analyst plate reader (Molecular Devices).
Animal experiments
Male 7-week-old C57BL6mice or db/dbmicewere purchased fromHarlan or
Jackson Laboratory and maintained in regular chow under the 12 hr light-
dark cycle. 0.5 3 109 plaque-forming units per recombinant adenovirus
were delivered by a systemic tail vain injection to mice that were anaesthe-
tized with Iso-Flurane. For measuring fasting blood glucose level, animals
were fasted for 16 hr or 5 hr with free access to water. Blood glucose was
monitored at the end of each fasting period for designated time points listed
in the figure legends. Liver tissues were collected at the end of experiments
and immediately frozen in liquid nitrogen. Western blot analysis was per-
formed with GFP antibody to check the relative infection.
Glucose tolerance test
5–7 days post injections, mice were fasted for 16 hr (WT) or 5 hr (db/dbmice)
prior to the glucose tolerance test. Mice were injected intraperitoneally with 2
g/kg body weight of glucose. Blood glucose levels were measured from tail
vein blood collected at the designated time periods listed in the figure leg-
ends using an automated glucose monitor (One Touch, Lifescan).
Insulin tolerance test
4–5 days post injections, 5 hr-fasted (WT) or ad lib fed (db/db mice) mice
were injected intraperitoneally with 1 unit/kg body weight of insulin. Blood
glucose levels were measured from tail vein blood collected at the desig-
nated time periods listed in the figure legends.
Fasting and refeeding experiments
Wild-type C57/Bl6 adult male mice (6 per group) were fed ad libitum, fasted
for 16 hr, or fasted for 24 hr and refed for 24 hr. Total RNAwas extracted from
liver samples in Trizol (Invitrogen) using the RNeasy kit with DNase treatment.
cDNA was generated using the high capacity cDNA archive kit (AppliedCELL METABOLISM : MAY 2006
PTP-MEG2 inhibits hepatic insulin signalingBiosystems). Real-time polymerase chain reaction (PCR) was performed
using Taqman probes labeled with carboxyfluorescein (FAM) dye for the
relevant genes (PTPN9: probe Mm00451036_m1; PEPCK: probe
Mm00440636_m1 from Applied Biosystems) with a probe for mouse ribo-
somal protein 36B4 (VIC labeled) as an internal standard. Real time PCR
was monitored on a Sequence Detection System 7900HT (Applied Biosys-
tems); reactions were run in triplicate.
Supplemental data
Supplemental data include five figures and two tables and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/3/5/367/
DC1/.
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